v" A monoclonal antibody termed "FR77" was obtained from a hybridoma clone established by fusion between P3x63Ag8.653 mouse myeloma cells and spleen cells of a Fischer F344 rat hyperimmune to syngeneic 9L/R3 glioma cells. Immunoperoxidase staining of various cultured cells showed that FR77 was reactive to both rat and human glioma cells, but was not reactive with other nonglioma cells. Immunohistochemical examination of paraffin-embedded or cryostat-frozen sections of various human tissues revealed that FR77 was strongly reactive with glioblastoma, grade III astrocytoma, and craniopharyngioma; partially reactive with intracerebral primitive neuroectodermal tumor, pineoblastoma, and desmoplastic medulloblastoma; and weakly reactive with low-grade astrocytoma. It was not reactive with other types of brain tumors and normal human tissues tested. The FR77-defined antigen was observed to be predominantly localized in the cytoplasm of antigen-bearing cells as suggested by the immunostaining pattern, but part of it was also expressed on the cell surface of glioma cells as demonstrated by a complement-mediated cytotoxic test. Fractionation of the antigenic component and periodic acid treatment of tumor tissue bearing the FR77-defined antigen indicated that the antigen is of a neutral glycolipid nature and that the antigenic determinant to FR77 is present on its sugar portion.
G
LIOMA is one of the major malignant brain tumors that occurs in the human, and monoclonal antibodies to glioma have been prepared aimed at enhancing its diagnosis and therapy. 3,5,22 ' 25' 27 In general, these monoclonal antibodies were prepared by xenogeneic immunization of animals and were found to recognize species-specific glioma-associated antigens. However, Peng, et aL, 15 described a mouse monoclonal antibody raised against rat glioma cells that was cross-reactive with a human glioma cell.
We have established a hybridoma clone from spleen cells of a rat that had been immunized with syngeneic glioma cells and have shown that a monoclonal antibody (FR77) from this hybridoma was selectively reactive with experimental rat glioma cellsJ 8 In the present paper, we show that this rat monoclonal antibody is cross-reactive with human glioma and with several other human brain tumors. We also describe the biochemical and physicochemical characteristics of the cross-species glioma-associated antigen detected by this monoclonal antibody.
Materials and Methods

Cell Lines
Several cell lines were used in this study. The 9L rat glioma cell 1'~9 is a well-established line induced with 1-methyl-1-nitrosourea in Fischer F344 rats. A 9L/R3 cell line, a subline of the 9L glioma that is resistant to ACNU(1-(4-amino-2-methylpyridimidine-5yl)-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride), was established and grown as described previouslyJ ~ Other tumor cell lines included a human glioma cell line KNS-42,13 a human astrocytoma cell line SK-MG-1, 3 a hu-man colon carcinoma cell line COLO-201, 2~ and a rat glioma cell line C67" A human glioma cell line KMK-9 was established in the laboratory at Kobe University from glioblastoma tissue of a 64-year-old Japanese woman. The cells grew as a monolayer. When these cells are inoculated subcutaneously into nude mice, serially transplantable tumor nodules are formed after 3 to 4 weeks. Staining by the immunoperoxidase method revealed that the KMK-9 cell line contained glial fibrillary acidic protein and S-100 protein.
Additional human tumor cell lines were obtained from various sources in Japan. These included the melanoma cell line Mm-I-JCK, the renal carcinoma cell line KO-RCC-I, the bladder carcinoma cell line HT-1197,16 the choriocarcinoma cell line BeWo, 14 and the neuroblastoma cell line NB-I.t All these ceils grew as a monolayer and were maintained in Eagle's minimum essential medium or RPMI-1640 medium containing 10% fetal calf serum.
Short-Term Cell Cultures
Normal human and rat skin fibroblasts were cultured by using the method of Carey, et al. 4 Various human brain-tumor tissues were taken from biopsy specimens removed from patients undergoing standard operative procedures. Sterile tumor specimens were dissected free of adherent normal tissue, mechanically dissociated into fragments about 0.5 cumm in size, incubated for 30 minutes at 37"C in 1000 U/ml of Disperse solution,~ and passed through a 100-tzm stainless steel mesh. These single-cell suspensions were plated on 60-ram Falcon plastic dishes. Cultured cells at subconfluency were passaged by treatment with 0.01% trypsin at 7-to 10-day intervals.
Tissue Samples
For immunohistochemical studies, normal and pathological human tissues were obtained at biopsy or autopsy performed for diagnostic purposes. These tissues would have been discarded unless otherwise used in this experiment. Tissues for paraffin embedding were fixed in 10% buffered formalin by means of standard procedures and were cut into 4-jzm thick sections. Tis-* Human glioma cell line KNS-42 was a gift from the Department of Neurosurgery, Neurological Institute, Kyushu University, Fukuoka, Japan; human astrocytoma cell line SK-MG-1 donated by Dr. T. Takahashi, Aichi Cancer Center Institute, Nagoya, Japan; and human colon carcinoma cell line COLO-201 and rat glioma cell line C6 were obtained from Flow Laboratories, Inc., Rockville, Maryland. 
Immunoperoxidase Staining of Cultured Cells
Cells (5 x 104) were seeded on 18 x 24-mm sterile coverslips 48 hours before assay. Coverslips containing cell monolayers were washed in phosphate-buffered saline (PBS) and fixed in 10% formaldehyde in PBS for 15 minutes at room temperature. After fixation, the coverslips were rinsed in PBS. Immunoperoxidase staining was performed on fixed cells with a biotin: avidin kitll using modifications of the method of Hsu and Raine. 9 Coverslips were treated with diluted normal rabbit serum for 20 minutes to eliminate the nonspecific binding of secondary antibody and were then overlaid with hybridoma supernatant containing monoclonal antibody FR77. The supernatant of P3x63Ag8.653 myeloma cells and 2% normal Fischer rat serum in PBS was used as a negative control. After 45 minutes of incubation at room temperature, the coverslips were washed for 15 minutes with three changes of PBS. Endogenous peroxidase was inhibited by treatment with 0.3% H202 in methanol for 15 minutes. Coverslips were overlaid with biotinylated rabbit anti-rat Ig for 30 minutes and avidin:biotin-conjugated horseradish peroxidase for 30 minutes, with rinses in PBS between each step. The peroxidase substrate, 3.3'-diaminobenzidine tetrahydrochloride (DAB: 3 mg in 10 ml of 0.05-M Tris-HCl, pH 7.6, in 0.01% hydrogen peroxide), was added, and the peroxidase reaction was allowed to continue for 5 minutes at room temperature. Excess DAB was then washed off for 5 minutes, and the slides were counterstained in hematoxylin, then dehydrated, cleared in xylene, and mounted.
Immunohistochemical Analysis
Paraffin-embedded and frozen sections were immunostained with monoclonal antibody FR77 by using the avidin-biotinylated peroxidase complex (ABC) as described above.
w Tissue Tek II manufactured by Lab-Tek Products, Naperville, Illinois.
II Biotin:avidin kit manufactured by Vector Laboratories, Inc., Burlingame, California.
Detection of human glioma-associated antigen
Cytotoxic Assay
Target cells (5 x 10 4) in 50 ul of culture medium were added to 50 ul of serially diluted hybridoma supernatant containing FR77. The cells and antibody were incubated at room temperature for 30 minutes followed by an additional 60 minutes with 50 ul of appropriately diluted normal rabbit serum as a source of complement. Cytotoxicity was determined by trypan blue dye exclusion. As a negative control, 2% rat serum in RPMI-1640 medium containing 10% fetal calf serum was used. Results were expressed as a cytotoxic index (CI), calculated as follows: 26
% of intact cells in test wells CI = 1 -% of intact cells in control wells"
A CI over 0.20 was estimated to be a significant positive reaction (p < 0.05).
Preparation of Glycolipid Fractions
The method for fractionation of glycolipids has been described previously. 12 Briefly, total lipid extract from human glioma KNS-42 cells was prepared and subjected to Folch partition followed by separation of acetylated glycolipids on a Florisil column* and deacetylation. 7'17 Neutral and acidic glycolipid fractions were then separated by using a diethylaminoethyl (DEAE)-Sephadex A-25 column. 28 For determination of the antigenic activities in the fractionated glycolipids, enzyme-linked immunosorbent assay was performed; 50-izl aliquots of the methanol solution, which contained glycolipids equivalent to those extracted from 1 x 105 cells, were added to the wells of Falcon flexible assay plates and dried in vacuo for 1 hour. The wells were filled with PBS containing 1% bovine serum albumin and incubated overnight at 4"C. After a wash with PBS, 100 #1 of hybridoma supernatant containing FR77 was added to the wells and the plates were incubated for 45 minutes at room temperature. Normal rat serum (2%) in PBS was used as a negative control for the monoclonal antibody incubation. The wells were washed four times with PBS and then treated with 100 ~1 of horseradish peroxidase-labeled rabbit anti-rat Ig~" for 30 minutes at room temperature. After washing, 100 ul of the enzyme substrate 2,2'-azino-di(3-ethylbenzthiazoline)-6-sulfonic acid was added to the wells. Absorbancy of the samples at 414 nm was measured by a spectrophotometer for multiple plates.~
Periodic Acid Treatment
In order to decompose carbohydrate moieties in an-* Florisil column prepared by Floridin Co., Tallahassee, Florida.
t Rabbit anti-rat immunoglobulin obtained from Cappel Laboratories, Inc., West Chester, Pennsylvania.
z~ Spectrophotometer manufactured by Immuno Reader N J-2000, Inter Med., Roskilde, Denmark. human -* Antigen expression was ascertained by immunoperoxidase staining as described in the Materials and Methods section. Reactivity score: ++ = strongly positive staining; + = moderately positive staining; + = weakly positive staining; -= negative staining.
tigen, frozen glioma tissue sections were preincubated at 4~ for I hour with 1% periodic acid solution in PBS. After three washes with PBS, the sections were immunostained using ABC as described above.
Results
Binding of FR77 to Human and Rat Culture Cells
The reactivity of the monoclonal antibody FR77 against established cell lines and short-term culture cells is shown in Table 1 . A reaction occurred with fixed human glioma Cells as well as rat glioma cells but not with other nonglioma cells of rat and human origin. The staining pattern of FR77 with these glioma cells was densely cytoplasmic, with perinuclear accumulation ( Fig. 1 upper left) .
Immunohistochemical Analysis of Human Tissue Sections
Immunoperoxidase staining reactivity of FR77 on formalin-fixed paraffin-embedded sections of normal and tumor tissues from humans is summarized in Table  2 . The FR77 reacted strongly with all glioblastoma samples ( Fig. 1 upper right) and with a high proportion of the astrocytoma samples ( Fig. 1 center left) . Lowgrade astrocytoma tissues were found to show a weak reaction with FR77. The FR77 was also reactive with craniopharyngioma samples but not with ependymoma, medulloblastoma, germinoma, hemangioblastoma, meningioma, neurinoma, pituitary adenoma, The results of immunohistochemical studies with FR77 on cryostat-frozen sections are shown in Table 3 . In accordance with the results obtained by paraffinembedded sections (Table 2) , FR77 reacted strongly with glioblastoma ( Fig. 1 center right) , malignant astrocytoma, and craniopharyngloma (Fig. 1 lower) . Although FR77 was not reactive with the medulloblastoma, it was focally reactive with the desmoplastic medulloblastoma and pineoblastoma tissue sections. The normal tissue samples and other brain-tumor tissues did not stain with FR77.
Complement-Mediated Cytotoxicity of FR 77
The results of cytotoxic assay are shown in Fig. 2 . Culture supernatant containing FR77 was cytotoxic to KNS-42 human glioma, KMK-9 human glioma, and 9L/R3 rat glioma cells, but was not cytotoxic to Mm-1-JCK human melanoma and HT-1197 human bladder cancer when rabbit serum was used as a complement source. 
Characterization o f Glioma-Associated Antigen Detected by F R 77
We performed several biochemical experiments to characterize properties of the interspecies cross-reactive glioma-associated antigen recognized by FR77. First, we attempted immunostaining of Western Blots 23 with FR77 following sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of glioma cell lysate. However, no antigenic peptides reactive with FR77 were identified. We analyzed the reactivity of FR77 to glycolipids prepared from the KNS-42 cell line. Enzyme-linked immunosorbent assay of the glycolipid fractions demonstrated that the antigen detected by FR77 resided in a neutral glycolipid fraction (Table 4) . Although it has been suspected that the antigenic determinant recognized by FR77 is present in a sugar portion of the antigen, we confirmed this by observing the antibody reactivity to glioma tissue sections treated with periodic acid. This treatment abolished the reactivity to FR77 (Fig. 3) , indicating that the antigenic determinant to FR77 is present on a sugar portion of the glycolipid molecule.
Discussion
In humans, unlike inbred animals, tumor specificity of monoclonal antibodies cannot easily be demonstrated. Since it has been reported that antibodies obtained by a syngeneic immunization procedure often show interspecies cross-reactivity, 24 we used this immunization system in an attempt to find monoclonal antibodies selective to glioma. In this paper we have demonstrated that rat monoclonal antibody FR77 raised against syngeneic rat glioma cells also reacts selectively with h u m a n glioma cells.
With regard to the antigen specificity of FR77 to culture cell lines, FR77 was found to be reactive with human glioma cell lines but not with human melanoma and neuroblastoma lines. This is contrary to the results of several other studies in which monoclonal antibodies detected neuroectodermal antigens c o m m o n to melanomas, gliomas, and neuroblastomas. 6'11'2~ Investigations with human brain-tumor tissues, either paraffinembedded or frozen sections, showed that FR77 was not reactive with normal human tissues such as brain, liver, kidney, lung, spleen, and skeletal muscle but was strongly reactive with all glioblastomas examined. Reactivity of the FR77 to grade III astrocytomas was also strong, but reactivity to low-grade astrocytomas was negative or very weak, indicating that expression of the FR77-defined antigen correlates with the level of malignancy of the astrocytoma. A primitive neuroectodermal fi00
J. Neurosurg. / Volume 65 /October, 1986 tumor in the cerebral hemisphere, a pineoblastoma, and desmoplastic medulloblastorna tissue were focally stained with FR77, showing that these premature tumors are heterogeneous and have some glioma-like elements as indicated by their antigenicity. The monoclonal antibody FR77 also reacted with craniopharyngioma tissues. Even though craniopharyngioma is a benign tumor, it is believed to originate from remnants of embryonal tissue. We have reported elsewhere Is that the FR77-defined antigen appears to be a kind of oncofetal antigen. Therefore, this oncofetal antigen may be present in the craniopharyngioma tissues. Observation of the immunostained cells indicated that the FR77-defined antigen is mainly located in the cytoplasm of the cells. However, as demonstrated by complement-mediated cytotoxicity test results, a portion of the antigen or the antigenic determinant was found to be localized on the cell surface. The finding that the antigenic component could not be detected by the immunoblotting method indicated either that the FR77-defined antigen was not a protein or that this antigen was sensitive to heat or SDS-PAGE treatment. Analysis by means of fractionated glycolipid components revealed that the antigen is of a neutral glycolipid nature. Since an antigenic determinant is generally not present in a lipid component and since the treatment of glioma tissues with periodic acid abolished the reactivity to FR77, it is quite probable that the FR77-defined antigenic determinant is present on carbohydrate chains of the antigen molecule. The definite character of the antigenic determinant is as yet unclear, but it is certain that the carbohydrate determinant is expressed by neoplastic transformation of human and rat glial cells. As described by Hakomori and Kannagi, 8 changes in glycolipid composition may be related to the transformation of normal cells. 8 Further analysis of this antigenic molecule could give a clue for defining the mechanism of glial cell transformation.
